Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

49.660
-0.540-1.08%
Volume:4.02M
Turnover:197.73M
Market Cap:329.59B
PE:35.97
High:50.200
Open:50.200
Low:48.020
Close:50.200
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:0.80
T/O Rate:1.56%
Dividend:0.23
Dividend Rate:0.47%
EPS(LYR):1.381
ROE:12.46%
ROA:7.02%
PB:4.37
PE(LYR):35.97
PS:8.99

Loading ...

Movement Alert|HENGRUI PHARMA Rises 3.57% in Regular Trading, Multiple Global Institutions Accumulate Shares Amid Accelerated Drug Approvals

Market Focus
·
Sep 29

Blackrock's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 7.32%, Says HKEX

Reuters
·
Sep 25

UBS Group Ag's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 5.23% on Sept 21 from 4.43% - HKEX

THOMSON REUTERS
·
Sep 25

HENGRUI PHARMA: UBS Group AG Acquires Shares, Long Position Rises to 5.23%

HK Disclosure
·
Sep 25

HENGRUI PHARMA: BlackRock, Inc. Acquires Shares, Long Position Rises to 7.32%

HK Disclosure
·
Sep 25

HENGRUI PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 6.7%

HK Disclosure
·
Sep 24

HENGRUI PHARMA: GIC Private Limited Disposes of Shares, Long Position Falls to 16.92%

HK Disclosure
·
Sep 24

Movement Alert|HENGRUI PHARMA Falls 3.01% in Regular Trading, Pharmaceuticals Sector Under Broad Selling Pressure

Market Focus
·
Sep 24

HENGRUI PHARMA Spends RMB 11.37 Million Buying Back 250,000 A-Shares on September 23

Stock News
·
Sep 23

Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approvals for Ten Drug Candidates

Stock News
·
Sep 23

Hengrui Pharma Gets Clinical Trial Approval for Chronic Kidney Disease Drug

MT Newswires Live
·
Sep 22

Hengrui Pharmaceuticals Gets China Approval for Tumor Drug Trial

MT Newswires Live
·
Sep 22

Hengrui Pharma's Unit Gets Nod to Trial HRS-1596 Tablets; Shares Down 3%

MT Newswires Live
·
Sep 22

Movement Alert|HENGRUI PHARMA Falls 3.04% in Regular Trading, Pulling Back After Prior Sessions Strong Rally Amid Broad Sector Weakness

Market Focus
·
Sep 22

Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approval for SHR-4595 Injection

Stock News
·
Sep 21

Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Stock News
·
Sep 21

Movement Alert|HENGRUI PHARMA Rises 3.11% in Regular Trading, Buyback Launched and Employee Stock Plan Unveiled Amid BlackRock Accumulation

Market Focus
·
Sep 21

HENGRUI PHARMA: BlackRock, Inc. Disposes, Long Position Falls to 6.99%

HK Disclosure
·
Sep 18

Hong Kong Stock Market Update | Hengrui Pharma Surges Nearly 4% on First A-Share Buyback as Analysts Eye Growth in Non-Oncology Portfolio

Stock News
·
Sep 18

Movement Alert|HENGRUI PHARMA Rises 3.78% in Regular Trading, First A-Share Buyback Executed as BlackRock Raises Stake to 7.68%

Market Focus
·
Sep 18